Glucose measurements are essential for diabetes management. Although the measurement of HbA_1c has been the traditional method for assessing glycaemic control, it does not reflect intra- or inter-day glycaemic excursions or identify periods of high or low blood glucose. Advancements in continuous glucose monitoring systems (CGMs) has enabled a greater insight into an individual's glycaemic control than what was once attainable by intermittent capillary blood sampling or from HbA_1c. CGMs track glucose concentrations in the body's interstitial fluid, providing near real-time glucose data over several days. Accordingly, there has been a push for additional CGM-derived glycaemic indices to be used to complement HbA_1c when assessing an individual's glycaemic control. This talk will cover the therapeutic use of CGMs in practice for people with diabetes and how they can also be used as a robust research tool.